Mateon Therapeutics (MATN) and Its Rivals Critical Contrast
Mateon Therapeutics (NASDAQ: MATN) is one of 93 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Mateon Therapeutics to related companies based on the strength of its dividends, analyst recommendations, institutional ownership, profitability, earnings, valuation and risk.
This is a breakdown of recent ratings and recommmendations for Mateon Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mateon Therapeutics Competitors||163||542||1199||16||2.56|
Mateon Therapeutics currently has a consensus price target of $2.00, indicating a potential upside of 325.70%. As a group, “Biotechnology” companies have a potential upside of 57.54%. Given Mateon Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Mateon Therapeutics is more favorable than its rivals.
Earnings & Valuation
This table compares Mateon Therapeutics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mateon Therapeutics||N/A||-$14.59 million||-0.87|
|Mateon Therapeutics Competitors||$223.74 million||$57.84 million||-0.62|
Mateon Therapeutics’ rivals have higher revenue and earnings than Mateon Therapeutics. Mateon Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Mateon Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Mateon Therapeutics’ rivals have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.
Insider and Institutional Ownership
8.6% of Mateon Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 2.3% of Mateon Therapeutics shares are owned by insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Mateon Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mateon Therapeutics Competitors||-917.30%||-187.05%||-24.43%|
Mateon Therapeutics rivals beat Mateon Therapeutics on 7 of the 12 factors compared.
About Mateon Therapeutics
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.